Join A/Prof Kara Britt, Co-Chair of the VCCC Alliance Accelerating Novel Therapies Steering Committee, and keynote speaker Prof Charles Swanton, a world-leading expert in cancer medicine and Cancer UK’s Chief Clinician Cancer Research UK, as we examine the latest news and views on cancer prevention and early detection in this full-day symposium.
The world of cancer prevention and early detection is constantly changing and evolving. The diverse roles of all those who contribute to better patient outcomes – from basic research to clinical trials, to primary care and specialist clinicians, and all those in between – means we rely on each other to ensure that collectively we are at the forefront of the latest knowledge and best practice in cancer prevention and early detection.
The PREDICT Symposium provides you with a rare opportunity to come together to share your insights and learn about current and emerging knowledge in this space. In conjunction with national and international leaders in the sector, we will explore opportunities for collaboration and provide direction on where to access the latest information across the breadth of the cancer prevention and early detection translation pipeline.
Discussions will focus on the following key areas:
We know that together, we’re better. We encourage you to be a part of this important conversation.
A/Prof Kara Britt leads the Breast Cancer Risk and Prevention Lab within the Cancer Evolution and Metastasis Program. She obtained her PhD from Monash University working on female reproductive endocrinology and undertook a CJ Martin fellowship at the Institute of Cancer Research (UK) under the mentorship of Alan Ashworth and Matthew Smalley. Her work has helped define why women in today’s society have an increased incidence of breast cancer. Her lab has been instrumental in developing pre-clinical models for prevention-based research.
A/Prof Britt has held Early and Mid-Career Victorian Cancer Agency Fellowships and a National Breast Cancer Foundation (NBCF) Early Career fellowship. Her work has been supported by NHMRC, Equity Trustees, NBCF, and the Basser Centre (USA). She also co-chairs the VCCC Accelerating Novel Therapies Program which aims to increase the number of new drugs translating through to the patients that need it most.
Dr Natalie Diepenhorst
Consumer Advocate
A/Prof Vivienne Milch
Medical Director, Cancer Australia
A/Prof Dan Buchanan
Principal Research Fellow, Colorectal Cancer Clinical Pathology, the University of Melbourne
Dr Rachel Joyce
Postdoctoral Research Fellow, the University of Melbourne
Prof Julia Brotherton
Professorial Fellow, Cancer Prevention Policy, Melbourne School of Population and Global Health, the University of Melbourne
A/Prof Nicole Rankin
Associate Professor in Evaluation & Implementation Science, Melbourne School of Population and Global Health, the University of Melbourne
Prof Paul James
Clinical Geneticist and Director, Parkville Familial Cancer Centre, Peter MacCallum Cancer Centre and Royal Melbourne Hospital; Head of Clinical Genetics, Royal Melbourne Hospital
Prof Mark Jenkins
Director of the Centre for Epidemiology & Biostatistics, School of Population & Global Health, the University of Melbourne
Dr Claire Nightingale
Senior Research Fellow, Melbourne School of Population and Global Health, the University of Melbourne
Ms Kate Broun
Head of Screening, Early Detection and Immunisation, Cancer Council Australia
A/Prof Ilias Goranitis
Principal Research Fellow, Health Economics, Melbourne School of Population and Global Health
A/Prof Jennifer McIntosh
Academic Specialist, Cancer Screening and Implementation Science Research, School of Population and Global Health
